Alzheimer's Drug Discovery Foundation

@TheADDF · New York, NY · joined 26 Feb 2009

The Alzheimer's Drug Discovery Foundation's mission is to rapidly accelerate the discovery and development of drugs to prevent, treat, and cure #Alzheimers.

18 423Followers

4 866Following

5 750Posts total

2.5KViews on collected posts

Últimas publicaciones

Alzheimer's Drug Discovery Foundation@TheADDF1 Sep

The ADDF’s Aaron Burstein spoke with @Inc about LM11A-31, an experimental therapy from ADDF-funded PharmatrophiX that may protect synapses and reduce harmful changes linked to both tau and amyloid in Alzheimer’s. https://t.co/FYDHFiguK4 599 views · 8 likes · 2 reposts · 0 replies Open on X →

Alzheimer's Drug Discovery Foundation@TheADDF27 Aug

The ADDF’s CEO, Isobel Coleman, has seen firsthand the extraordinary progress in Alzheimer’s research. She shares how the ADDF will carry that progress forward through scientific expertise, strategic investment, and collaboration. https://t.co/VCojaQSTRu https://t.co/trs57iAfHY 302 views · 3 likes · 0 reposts · 0 replies Open on X →

Alzheimer's Drug Discovery Foundation@TheADDF20 Aug

The FDA clearance of @C2NDiagnostics' PrecivityAD2 blood test marks another major milestone in the rapid shift toward more accessible and scalable Alzheimer’s diagnostics, moving Alzheimer’s care closer to precision medicine. https://t.co/nsoBdGceDd https://t.co/mBfBAnlCNN 526 views · 7 likes · 1 reposts · 0 replies Open on X →

Alzheimer's Drug Discovery Foundation@TheADDF19 Aug

The ADDF's CEO, Isobel Coleman, shares her vision for the ADDF’s next chapter, driving greater impact across Alzheimer’s research while building on its scientific legacy and catalyzing progress in drug development, biomarkers, and prevention. https://t.co/VCojaQSTRu 371 views · 2 likes · 0 reposts · 0 replies Open on X →

Alzheimer's Drug Discovery Foundation@TheADDF4 Aug

Tau research is gaining momentum as the field looks beyond amyloid. In @AARP, the ADDF's Interim Chief Science Officer Laura Nisenbaum explains why tau is closely tied to cognitive decline and why it remains an important target in Alzheimer’s. https://t.co/zz0CYRV3nD 681 views · 1 likes · 1 reposts · 0 replies Open on X →

Frente a cuentas del mismo tamaño

5 publicaciones de los últimos 90 días, junto al rango de 10K–100K seguidores. alcance normal para su tamaño, reacción más débil que la mayoría.

Visualizaciones medianas526esta cuenta924mediana de 10K–100K

Alcance, %2.86%esta cuenta3.62%mediana de 10K–100K

Interacción, %0.99%esta cuenta1.52%mediana de 10K–100K

Métrica	Esta cuenta	Mediana de 10K–100K	Proporción
Visualizaciones medianas por publicación	526	924	0.57×
Alcance (visualizaciones ÷ seguidores)	2.86%	3.62%	0.79×
Tasa de interacción	0.99%	1.52%	0.65×

Otras cuentas de este rango → Comparar con otra cuenta → Cómo se construyen estas referencias →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

6814 Aug

37119 Aug

52620 Aug

30227 Aug

5991 Sep

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.29%4 Aug

0.54%19 Aug

1.52%20 Aug

0.99%27 Aug

1.67%1 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes80.8%21 in total

Reposts15.4%4 in total

Bookmarks3.8%1 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.